Profusa, Inc. (NASDAQ: PFSA) shareholders approved all proposals presented at the Company’s 2026 Annual Meeting of Shareholders held on June 23, 2026. The approvals encompass the acquisition of the PanOmics multi-omics diagnostics platform, a debt-conversion initiative aimed at strengthening the balance sheet, and the authorization of a reverse stock split. These strategic moves are designed to enhance the company's technological capabilities and financial structure.

The approval of the PanOmics acquisition marks a significant expansion of Profusa's diagnostic offerings. By integrating multi-omics capabilities, Profusa aims to broaden its impact in the digital health sector. Concurrently, the debt-conversion plan was endorsed to improve the company's balance sheet, providing greater financial flexibility for future operations.

Shareholders also authorized a reverse stock split, granting the board the ability to adjust the capital structure as needed. This measure is often utilized to maintain compliance with listing standards or to attract a broader base of institutional investors. The specific ratio and timing of the split will be determined at the discretion of the board.

The following table summarizes the key outcomes of the shareholder meeting:

These decisions reflect Profusa's commitment to advancing its biosensing technologies and ensuring long-term shareholder value. The company will proceed with the implementation of these approved initiatives in accordance with regulatory requirements.

Profusa, Inc. (NASDAQ: PFSA), a digital health company, has submitted its response package to European Notified Body GMED as part of the ongoing CE Mark review process for its Lumee Oxygen Platform. The submission follows the successful completion of Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED under the Medical Device Regulation (MDR) conformity assessment process. This milestone supports Profusa's broader strategy to commercialize the technology in Europe.

The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting validation information. The CE Mark review process remains ongoing, and there is no assurance regarding the timing or outcome of GMED's assessment.

Ben Hwang, Ph.D., Profusa's Chairman and Chief Executive Officer, emphasized the significance of the submission. "Submitting our responses to GMED marks another meaningful milestone in the CE Mark review process," Hwang said. "We appreciate GMED's continued engagement throughout the assessment and remain committed to working collaboratively with the agency as it completes its review."

The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through Profusa's proprietary tissue-integrated biosensor technology. The platform aims to provide clinicians with objective tissue perfusion data to support treatment decision-making and patient monitoring.

Profusa, based in Berkeley, CA, is a commercial-stage digital health company focused on developing tissue-integrated sensors for medical use. The company's long-lasting, injectable biosensors and intelligent data platform aim to provide personalized biochemical data for clinicians. Profusa will continue to support the review process and provide updates on material regulatory milestones as appropriate.